Bioventix's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 107.15.
Bioventix's Days Inventory for the
six
months ended in Dec. 2025 was 254.63.
Bioventix's Days Payable for the
six
months ended in Dec. 2025 was 368.42.
Therefore, Bioventix's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was -6.64.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Bioventix Cash Conversion Cycle Related Terms
Bioventix Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Bioventix's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:51B vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Bioventix's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioventix Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioventix's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Bioventix's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Bioventix's Cash Conversion Cycle for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioventix (FRA:51B) has a Cash Conversion Cycle of -6.64 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Bioventix and its competitors.
Is Bioventix's Cash Conversion Cycle too high?
Bioventix's current Cash Conversion Cycle is -6.64. Overall, Bioventix has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioventix's Cash Conversion Cycle compare to VRTX and REGN?
Bioventix's Cash Conversion Cycle of -6.64 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 104.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 104.03, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Bioventix and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioventix's current Cash Conversion Cycle is -6.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventix stock overvalued right now?
Based on GuruFocus' analysis, Bioventix (FRA:51B) is currently considered Significantly Undervalued. The stock's GF Value™ is €38.68, compared to a current price of €17.50 — trading 54.8% below its estimated fair value. The current Cash Conversion Cycle is -6.64. Bioventix's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Bioventix (FRA:51B), the current Cash Conversion Cycle is -6.64 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioventix (FRA:51B) Overvalued in 2026?
Based on GuruFocus' analysis, Bioventix stock appears to be undervalued.
The current stock price of €17.50 is trading 54.8% below its estimated GF Value™ of €38.68.
GuruFocus considers Bioventix to be Significantly Undervalued.
Key valuation signals for FRA:51B:
Cash Conversion Cycle: -6.64
GF Value™: €38.68 vs. price of €17.50 (54.8% below fair value)
No single metric tells the full story. See the FRA:51B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
64GF Score
Get the complete analysis for FRA:51B
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:51B has been successfully added to your 
